Literature DB >> 16914212

Replication efficiency of chimeric replicon containing NS5A-5B genes derived from HCV-infected patient sera.

Rakesh L Tripathi1, Preethi Krishnan, Yupeng He, Tim Middleton, Tami Pilot-Matias, Chih-Ming Chen, Daryl T Y Lau, Stanley M Lemon, Hongmei Mo, Warren Kati, Akhteruzzaman Molla.   

Abstract

A transient subgenomic replicon-based shuttle vector system has been developed to investigate how genetic heterogeneity affects HCV replication efficiency. Individual NS5A or NS5B genes or cassettes containing both NS5A and NS5B genes were amplified from "quasispecies" pools derived from HCV genotype 1a or 1b patient sera using RT-PCR and cloned into their respective shuttle vectors. All shuttle vectors containing NS5A or NS5A-5B genes were constructed with the S2204I "adaptive" mutation because replicons lacking the S2204I mutation replicated poorly. Gene sequences of the quasispecies pools within either genotype 1a or 1b patient samples ranged from 94 to 95% in identity. The replication capacity of 1b shuttle vectors containing patient-derived NS5A or NS5B genes averaged 67 and 75%, respectively, relative to the laboratory-optimized 1b replicon. In contrast, the replication efficiencies of both 1a and 1b shuttle vectors containing patient-derived NS5A-5B gene cassettes averaged around 2% relative to the respective laboratory-optimized replicon. All patient-derived replicons were tested in a transient assay for their sensitivity to either interferon-alpha (IFN-alpha) or to the polymerase inhibitor A-782759. Despite the differences in replication efficiency, IC(50) values measured for most of the patient-derived replicons were equivalent to the respective values measured in the control laboratory strain replicons. These results demonstrate that patient sequence heterogeneity affects replication efficiency whenever patient-derived NS5A-5B genes are inserted into the laboratory-optimized replicon. The findings also demonstrate the utility of the shuttle vector system to test patient-derived gene sequences for sensitivity to IFN-alpha and to small molecule inhibitors.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16914212     DOI: 10.1016/j.antiviral.2006.07.005

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  15 in total

1.  In vitro and in vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of hepatitis C virus NS5A.

Authors:  Preethi Krishnan; Jill Beyer; Neeta Mistry; Gennadiy Koev; Thomas Reisch; David DeGoey; Warren Kati; Andrew Campbell; Laura Williams; Wangang Xie; Carolyn Setze; Akhteruzzaman Molla; Christine Collins; Tami Pilot-Matias
Journal:  Antimicrob Agents Chemother       Date:  2014-12-01       Impact factor: 5.191

2.  Activity of a potent hepatitis C virus polymerase inhibitor in the chimpanzee model.

Authors:  Chih-Ming Chen; Yupeng He; Liangjun Lu; Hock Ben Lim; Rakesh L Tripathi; Tim Middleton; Lisa E Hernandez; David W A Beno; Michelle A Long; Warren M Kati; Todd D Bosse; Daniel P Larson; Rolf Wagner; Robert E Lanford; William E Kohlbrenner; Dale J Kempf; Tami J Pilot-Matias; Akhteruzzaman Molla
Journal:  Antimicrob Agents Chemother       Date:  2007-10-01       Impact factor: 5.191

3.  Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system.

Authors:  Yupeng He; Martin S King; Dale J Kempf; Liangjun Lu; Hock Ben Lim; Preethi Krishnan; Warren Kati; Timothy Middleton; Akhteruzzaman Molla
Journal:  Antimicrob Agents Chemother       Date:  2007-12-17       Impact factor: 5.191

4.  Preclinical characterization of PF-00868554, a potent nonnucleoside inhibitor of the hepatitis C virus RNA-dependent RNA polymerase.

Authors:  Stephanie T Shi; Koleen J Herlihy; Joanne P Graham; Jim Nonomiya; Sadayappan V Rahavendran; Heather Skor; Rebecca Irvine; Susan Binford; John Tatlock; Hui Li; Javier Gonzalez; Angelica Linton; Amy K Patick; Cristina Lewis
Journal:  Antimicrob Agents Chemother       Date:  2009-03-23       Impact factor: 5.191

5.  In vitro activity and resistance profile of dasabuvir, a nonnucleoside hepatitis C virus polymerase inhibitor.

Authors:  Warren Kati; Gennadiy Koev; Michelle Irvin; Jill Beyer; Yaya Liu; Preethi Krishnan; Thomas Reisch; Rubina Mondal; Rolf Wagner; Akhteruzzaman Molla; Clarence Maring; Christine Collins
Journal:  Antimicrob Agents Chemother       Date:  2014-12-22       Impact factor: 5.191

6.  Antiviral drugs against hepatitis C virus.

Authors:  Sidra Rehman; Usman A Ashfaq; Tariq Javed
Journal:  Genet Vaccines Ther       Date:  2011-06-23

7.  Resistance analysis of baseline and treatment-emergent variants in hepatitis C virus genotype 1 in the AVIATOR study with paritaprevir-ritonavir, ombitasvir, and dasabuvir.

Authors:  Preethi Krishnan; Rakesh Tripathi; Gretja Schnell; Thomas Reisch; Jill Beyer; Michelle Irvin; Wangang Xie; Lois Larsen; Daniel Cohen; Thomas Podsadecki; Tami Pilot-Matias; Christine Collins
Journal:  Antimicrob Agents Chemother       Date:  2015-06-22       Impact factor: 5.191

8.  Identification of determinants involved in initiation of hepatitis C virus RNA synthesis by using intergenotypic replicase chimeras.

Authors:  Marco Binder; Doris Quinkert; Olga Bochkarova; Rahel Klein; Nikolina Kezmic; Ralf Bartenschlager; Volker Lohmann
Journal:  J Virol       Date:  2007-03-07       Impact factor: 5.103

9.  Development of intergenotypic chimeric replicons to determine the broad-spectrum antiviral activities of hepatitis C virus polymerase inhibitors.

Authors:  Koleen J Herlihy; Joanne P Graham; Robert Kumpf; Amy K Patick; Rohit Duggal; Stephanie T Shi
Journal:  Antimicrob Agents Chemother       Date:  2008-08-11       Impact factor: 5.191

10.  Regulation of hepatitis C virus replication by nuclear translocation of nonstructural 5A protein and transcriptional activation of host genes.

Authors:  Muhammad Ahmad Maqbool; Mohamed R Imache; Martin R Higgs; Sophie Carmouse; Jean-Michel Pawlotsky; Hervé Lerat
Journal:  J Virol       Date:  2013-03-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.